Bone health in glucocorticoid-treated childhood acute lymphoblastic leukemia
Lilly Velentza, Farasat Zaman, Lars Sävendahl
Abstract
Glucocorticoids (GCs) are widely used in the treatment of childhood acute lymphoblastic leukemia (ALL), but their long-term use is also associated with bone-related morbidities. Among others, growth deficit, decreased bone mineral density (BMD) and increased fracture rate are well-documented and severely impact quality of life. Unfortunately, no efficient treatment for the management of bone health impairment in patients and survivors is currently available. The overall goal of this review is to discuss the existing data on how GCs impair bone health in pediatric ALL and attempts made to minimize these side effects.
Topics & Concepts
Bone healthMedicineBone mineralGlucocorticoidLymphoblastic LeukemiaQuality of life (healthcare)PediatricsIntensive care medicineOncologyInternal medicineLeukemiaOsteoporosisNursingAcute Lymphoblastic Leukemia researchChildhood Cancer Survivors' Quality of LifeNeonatal Respiratory Health Research